V

Vaxcyte

Develops broad-spectrum vaccines for bacterial infections

Scientist 2 - Analytical Development

Full-Time
$146k - $171k+ Equity
Senior, Expert
Bachelor's, Master's, PhD
San Carlos, CA, USA
HybridOn-site at least four days per week.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A PhD with 2–5 years, a master's degree with 7+ years, or a bachelor's degree with 10+ years of relevant industry experience in analytical development, quality control, or a related field is required; other combinations of education and experience may be considered.
  • Hands-on experience with multiple analytical techniques, such as ultraviolet-visible spectroscopy, high-performance or ultra-performance liquid chromatography, capillary electrophoresis, sodium dodecyl sulfate polyacrylamide gel electrophoresis, imaged capillary isoelectric focusing, liquid chromatography, mass spectrometry, enzyme kinetics, colorimetric and fluorescent plate-based assays, enzyme-linked immunosorbent assay, Western blot, and polymerase chain reaction.
  • Strong knowledge of analytical chemistry or biochemistry principles applied to assay development and control strategies.
  • Ability to troubleshoot non-routine assay and instrument issues using structured root-cause analysis and data-driven decision-making.
  • Proficiency with analytical software, data-processing workflows, and statistical tools.
  • Ability to independently plan and prioritize work, manage multiple projects, and meet timelines with minimal supervision.
  • Ability to work in a laboratory environment for extended periods.
  • Ability to lift up to 25 pounds.
  • Personal protective equipment is required.
Responsibilities
  • Contribute to method development, optimization, and qualification or validation readiness activities.
  • Design and execute experiments to evaluate critical method parameters and define appropriate system suitability and control strategies.
  • Troubleshoot assay and instrument performance issues, identify likely root causes, implement corrective actions, and document outcomes and recommendations.
  • Support or execute method transfers, including protocol preparation, training support, execution at receiving laboratories, and resolution of transfer issues.
  • Author and revise analytical methods, standard operating procedures, protocols, and technical reports, documenting experimental rationale, results, and conclusions for internal review and stakeholder communication.
  • Partner with cross-functional teams to define analytical plans, meet project timelines, and deliver high-quality outputs.
  • Communicate experimental progress, data interpretation, and emerging risks; propose mitigation plans and align next steps with stakeholders.
  • Contribute to a compliant, safety-focused, scientifically rigorous laboratory culture and model good documentation practices and data integrity expectations.
  • Train and mentor junior staff and new team members on assays, workflows, and troubleshooting; provide day-to-day technical guidance and feedback.
  • Perform routine and non-routine analytical testing using methods such as high-performance or ultra-performance liquid chromatography, size-exclusion chromatography, capillary electrophoresis, ultraviolet-visible spectroscopy, enzyme-linked immunosorbent assay, electrophoresis, plate-based assays, and other biochemical or biophysical techniques.
  • Execute assays according to approved methods, standard operating procedures, and applicable quality standards, identifying and troubleshooting common issues.
  • Process and interpret data; summarize results, trends, and potential risks, and escalate complex findings for review and decision-making.
  • Maintain accurate, timely documentation in laboratory notebooks or electronic systems and contribute to technical communications for project and cross-functional stakeholders.
  • Coordinate routine instrument maintenance and service activities, interface with vendors as needed, and support timely issue resolution.
  • Maintain laboratory organization, cleanliness, and compliant material labeling and storage practices.
  • Manage inventory of reagents, standards, and consumables; initiate procurement, track critical supplies, and support forecasting to avoid stockouts.
  • Follow environmental health and safety policies and laboratory safety practices.
  • Handle chemicals and biological materials safely and in compliance with regulatory requirements.
  • Ensure proper waste disposal and adherence to hazardous-material handling procedures.
  • Support audit and inspection readiness activities where applicable.
Desired Qualifications
  • Experience independently driving method development or optimization activities.

About the company

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Carlos, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • All three OPUS adult Phase 3 trials fully enrolled by August 2026, de-risking execution.
  • The FDA expanded VAX-31 Breakthrough Therapy designation in May 2025 to include pneumonia.
  • Thermo Fisher’s up-to-$1 billion agreement and Lonza manufacturing build support commercial readiness.

What critics are saying

  • VAX-31 OPUS-1 data shifted to October 2026, compressing launch timelines.
  • Q2 2026 burn reached $284.3 million, while cash funding depends on dilution.
  • Pfizer Prevnar 20 and Merck Capvaxive already control adult pneumococcal vaccination, threatening VAX-31 adoption.

What makes Vaxcyte unique

  • Vaxcyte’s XpressCF platform produced VAX-31, a 31-valent PCV, on September 10, 2026.
  • OPUS trials were finalized with FDA alignment for a planned BLA submission.
  • Thermo Fisher and Lonza manufacturing deals lock commercial capacity across U.S. and Europe.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-2%

2 year growth

0%
BBNS
Oct 7th, 2026
Biotech stocks to consider - october 5th.

Biotech stocks to consider - october 5th. Moderna, Vaxcyte, and Amgen are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies involved in developing and commercializing biotechnology products, such as pharmaceuticals, medical devices, diagnostics, and gene or cell therapies. For investors, these stocks can offer significant growth potential but often carry elevated risks due to clinical-trial outcomes, regulatory decisions, high research costs, and uncertain profitability. These companies had the highest dollar trading volume of any Biotech stocks within the last several days. Moderna (MRNA). Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. Discover more Shop Handbags View Collections Discover Luxury Vaxcyte (PCVX). Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. Amgen (AMGN). Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Yahoo Finance
Oct 6th, 2026
Vaxcyte's VAX-31 vaccine matches Pfizer's $6.49B Prevnar on all serotypes in Phase 3 trial

Vaxcyte announced its 31-valent pneumococcal vaccine, VAX-31, met all primary endpoints in a Phase 3 trial with 4,047 participants. The vaccine matched Pfizer's Prevnar 20 on all 20 shared serotypes and Merck's Capvaxive on 17 of 19 shared serotypes. Pfizer's Prevnar franchise generated $6.49 billion in 2025, representing roughly 10% of the company's $62.58 billion total revenue. The franchise grew just 1% last year, with Pfizer citing lower US market share. Merck's Capvaxive brought in $759 million in 2025, about 1% of its revenue. Pfizer trades at 9.87x forward earnings whilst Merck trades at 16.36x. Vaxcyte plans to file for approval in the first half of 2028. The company expects results from two additional trials in the first half of 2027.

Minyanville
Oct 5th, 2026
Vaxcyte launches dual $500M offerings of stock and convertible notes due 2032

Vaxcyte, a clinical-stage vaccine innovation company, has commenced underwritten public offerings of $500 million in common stock and pre-funded warrants, alongside $500 million in convertible senior notes due 2032. The company intends to grant underwriters a 30-day option to purchase an additional $75 million in each offering to cover over-allotments. The offerings are not contingent on each other and remain subject to market conditions. Jefferies, Leerink Partners, BofA Securities, and others are serving as joint book-running managers. Vaxcyte plans to use proceeds to fund clinical development of its VAX-31 adult and paediatric programmes, manufacturing scale-up, commercial investments for anticipated US launch, and research into early-stage pipeline vaccine candidates. The notes will accrue interest payable semi-annually and mature on 15 October 2032.

Yahoo Finance
Oct 5th, 2026
Vaxcyte soars 50% as pneumococcal vaccine beats Pfizer and Merck in late-stage trial

Vaxcyte's experimental pneumococcal vaccine VAX-31 met all main efficacy objectives in its first late-stage trial, sending shares soaring 50% and pushing the company's market value past $12 billion. The vaccine matched Pfizer's Prevnar 20 and Merck's Capvaxive in protecting against 28 bacterial strains and proved superior against three unique strains in adults aged 50 and older. VAX-31 was inferior on two strains using a stricter statistical threshold, though analysts called this a "near best-case scenario." Vaxcyte's shot targets the pneumococcal vaccine market worth $8 billion annually, dominated by Pfizer's franchise which earned over $6 billion last year. VAX-31 covers more than 30 strains, offering broader protection than existing vaccines. The company will report results from two additional late-stage trials next year before seeking regulatory approval.

STAT
Oct 5th, 2026
Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market.

Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market. Biotech company's pneumococcal vaccine hit primary endpoints in late-stage study. Oct. 5, 2026 General Assignment Reporter Vaxcyte said Monday that its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the California-based biotech to compete with Pfizer and Merck. Vaxcyte's shot, VAX-31, is designed to protect against 31 serotypes, or strains, of bacteria that can cause pneumococcal disease, including pneumonia, compared to 20 strains for Pfizer's Prevnar and 21 strains for Merck's Capvaxive. In the trial, just over 3,500 adults age 50 and older were randomized to receive VAX-31, Prevnar, or Capvaxive. Investigators then measured the strength of their antibody responses against different strains.